Literature DB >> 19411632

Survivin mediates aberrant hematopoietic progenitor cell proliferation and acute leukemia in mice induced by internal tandem duplication of Flt3.

Seiji Fukuda1, Pratibha Singh, Akira Moh, Mariko Abe, Edward M Conway, H Scott Boswell, Seiji Yamaguchi, Xin-Yuan Fu, Louis M Pelus.   

Abstract

Internal tandem duplication mutations in the Flt3 tyrosine kinase gene (ITD-Flt3) and overexpression of Survivin are frequently found in patients with acute myeloid leukemia (AML). We investigated whether Survivin mediates the enhanced survival of primary hematopoietic progenitor cells (HPCs) resulting from ITD-Flt3 signaling. Ectopic ITD-Flt3 mutants increased Survivin expression in Ba/F3 cells downstream of PI3-kinase/Akt. Treatment of ITD-Flt3(+) human MV4-11 leukemia cells with the ITD-Flt3 inhibitor SU5416 reduced Survivin expression and inhibited cell proliferation. ITD-Flt3 dramatically increased the number of primary mouse marrow c-kit(+), Sca-1(+), Lin(Neg) cells and colony-forming unit granulocyte-macrophages (CFU-GMs) able to proliferate in the absence of growth factors, whereas Survivin deletion significantly reduced growth factor-independent proliferation and increased apoptosis, which was further accentuated by SU5416. Ectopic ITD-Flt3 reduced differentiation of Lin(Neg) marrow cells cultured with granulocyte-macrophage colony-stimulating factor (GM-CSF) plus stem cell factor, which was partially blocked by Survivin deletion. In addition, Survivin deletion decreased secondary colony formation induced by ITD-Flt3. Dominant-negative (dn)-Survivin delayed development of acute leukemia in mice that received a transplant of Ba/F3 cells expressing ITD-Flt3. These results suggest that Survivin regulates expansion of ITD-Flt3-transformed HPCs with self-renewal capability and development of ITD-Flt3(+) acute leukemia and that antagonizing Survivin may provide therapeutic benefit for patients with acute leukemia expressing ITD-Flt3.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19411632      PMCID: PMC2714213          DOI: 10.1182/blood-2008-11-188714

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  50 in total

1.  An anti-apoptotic protein human survivin is a direct inhibitor of caspase-3 and -7.

Authors:  S Shin; B J Sung; Y S Cho; H J Kim; N C Ha; J I Hwang; C W Chung; Y K Jung; B H Oh
Journal:  Biochemistry       Date:  2001-01-30       Impact factor: 3.162

2.  Constitutive activation of FLT3 stimulates multiple intracellular signal transducers and results in transformation.

Authors:  K F Tse; G Mukherjee; D Small
Journal:  Leukemia       Date:  2000-10       Impact factor: 11.528

3.  Flt3 mutations from patients with acute myeloid leukemia induce transformation of 32D cells mediated by the Ras and STAT5 pathways.

Authors:  M Mizuki; R Fenski; H Halfter; I Matsumura; R Schmidt; C Müller; W Grüning; K Kratz-Albers; S Serve; C Steur; T Büchner; J Kienast; Y Kanakura; W E Berdel; H Serve
Journal:  Blood       Date:  2000-12-01       Impact factor: 22.113

4.  Expression and prognostic significance of survivin in de novo acute myeloid leukaemia.

Authors:  C Adida; C Recher; E Raffoux; M T Daniel; A L Taksin; P Rousselot; F Sigaux; L Degos; D C Altieri; H Dombret
Journal:  Br J Haematol       Date:  2000-10       Impact factor: 6.998

5.  Internal tandem duplication of Flt3 modulates chemotaxis and survival of hematopoietic cells by SDF1alpha but negatively regulates marrow homing in vivo.

Authors:  Seiji Fukuda; Louis M Pelus
Journal:  Exp Hematol       Date:  2006-08       Impact factor: 3.084

Review 6.  Survivin, a cancer target with an emerging role in normal adult tissues.

Authors:  Seiji Fukuda; Louis M Pelus
Journal:  Mol Cancer Ther       Date:  2006-05       Impact factor: 6.261

7.  Prevalence and prognostic significance of Flt3 internal tandem duplication in pediatric acute myeloid leukemia.

Authors:  S Meshinchi; W G Woods; D L Stirewalt; D A Sweetser; J D Buckley; T K Tjoa; I D Bernstein; J P Radich
Journal:  Blood       Date:  2001-01-01       Impact factor: 22.113

8.  Disruption of the inhibitor of apoptosis protein survivin sensitizes Bcr-abl-positive cells to STI571-induced apoptosis.

Authors:  Zhanxiang Wang; Janardhan Sampath; Seiji Fukuda; Louis M Pelus
Journal:  Cancer Res       Date:  2005-09-15       Impact factor: 12.701

9.  Knock-in of an internal tandem duplication mutation into murine FLT3 confers myeloproliferative disease in a mouse model.

Authors:  Li Li; Obdulio Piloto; Ho Bao Nguyen; Kathleen Greenberg; Kogo Takamiya; Frederick Racke; David Huso; Donald Small
Journal:  Blood       Date:  2008-02-01       Impact factor: 22.113

10.  FLT3 mutations confer enhanced proliferation and survival properties to multipotent progenitors in a murine model of chronic myelomonocytic leukemia.

Authors:  Benjamin H Lee; Zuzana Tothova; Ross L Levine; Kristina Anderson; Natalija Buza-Vidas; Dana E Cullen; Elizabeth P McDowell; Jennifer Adelsperger; Stefan Fröhling; Brian J P Huntly; Miloslav Beran; Sten Eirik Jacobsen; D Gary Gilliland
Journal:  Cancer Cell       Date:  2007-10       Impact factor: 31.743

View more
  23 in total

1.  Survivin is highly expressed in CD34(+)38(-) leukemic stem/progenitor cells and predicts poor clinical outcomes in AML.

Authors:  Bing Z Carter; Yihua Qiu; Xuelin Huang; Lixia Diao; Nianxiang Zhang; Kevin R Coombes; Duncan H Mak; Marina Konopleva; Jorge Cortes; Hagop M Kantarjian; Gordon B Mills; Michael Andreeff; Steven M Kornblau
Journal:  Blood       Date:  2012-05-29       Impact factor: 22.113

2.  Cytoplasmic localization of wild-type survivin is associated with constitutive activation of the PI3K/Akt signaling pathway and represents a favorable prognostic factor in patients with acute myeloid leukemia.

Authors:  Juana Serrano-López; Josefina Serrano; Vianihuini Figueroa; Antonio Torres-Gomez; Salvador Tabares; Javier Casaño; Noemi Fernandez-Escalada; Joaquín Sánchez-Garcia
Journal:  Haematologica       Date:  2013-06-28       Impact factor: 9.941

3.  BIRC5 (survivin) splice variant expression correlates with refractory disease and poor outcome in pediatric acute myeloid leukemia: a report from the Children's Oncology Group.

Authors:  Andrew S Moore; Todd A Alonzo; Robert B Gerbing; Beverly J Lange; Nyla A Heerema; Janet Franklin; Susana C Raimondi; Betsy A Hirsch; Alan S Gamis; Soheil Meshinchi
Journal:  Pediatr Blood Cancer       Date:  2013-10-11       Impact factor: 3.167

4.  Activation of the PI3K/AKT pathway by microRNA-22 results in CLL B-cell proliferation.

Authors:  F Palacios; C Abreu; D Prieto; P Morande; S Ruiz; T Fernández-Calero; H Naya; G Libisch; C Robello; A I Landoni; R Gabus; G Dighiero; P Oppezzo
Journal:  Leukemia       Date:  2014-05-14       Impact factor: 11.528

5.  Rapid Mobilization Reveals a Highly Engraftable Hematopoietic Stem Cell.

Authors:  Jonathan Hoggatt; Pratibha Singh; Tiffany A Tate; Bin-Kuan Chou; Shruti R Datari; Seiji Fukuda; Liqiong Liu; Peter V Kharchenko; Amir Schajnovitz; Ninib Baryawno; Francois E Mercier; Joseph Boyer; Jason Gardner; Dwight M Morrow; David T Scadden; Louis M Pelus
Journal:  Cell       Date:  2017-12-07       Impact factor: 41.582

6.  Blockade of prostaglandin E2 signaling through EP1 and EP3 receptors attenuates Flt3L-dependent dendritic cell development from hematopoietic progenitor cells.

Authors:  Pratibha Singh; Jonathan Hoggatt; Peirong Hu; Jennifer M Speth; Seiji Fukuda; Richard M Breyer; Louis M Pelus
Journal:  Blood       Date:  2011-11-22       Impact factor: 22.113

7.  p53 activation of mesenchymal stromal cells partially abrogates microenvironment-mediated resistance to FLT3 inhibition in AML through HIF-1α-mediated down-regulation of CXCL12.

Authors:  Kensuke Kojima; Teresa McQueen; Ye Chen; Rodrigo Jacamo; Marina Konopleva; Naoki Shinojima; Elizabeth Shpall; Xuelin Huang; Michael Andreeff
Journal:  Blood       Date:  2011-08-25       Impact factor: 22.113

8.  Overexpression of survivin initiates hematologic malignancies in vivo.

Authors:  S Small; G Keerthivasan; Z Huang; S Gurbuxani; J D Crispino
Journal:  Leukemia       Date:  2010-09-30       Impact factor: 11.528

9.  Internal tandem duplication of FLT3 deregulates proliferation and differentiation and confers resistance to the FLT3 inhibitor AC220 by Up-regulating RUNX1 expression in hematopoietic cells.

Authors:  Tomohiro Hirade; Mariko Abe; Chie Onishi; Takeshi Taketani; Seiji Yamaguchi; Seiji Fukuda
Journal:  Int J Hematol       Date:  2015-11-21       Impact factor: 2.490

Review 10.  Graft-versus-leukemia effect of nonmyeloablative stem cell transplantation.

Authors:  Masahiro Imamura; Junji Tanaka
Journal:  Korean J Intern Med       Date:  2009-11-27       Impact factor: 3.165

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.